Tissue specific LRRK2 interactomes reveal a distinct striatal functional unit

Mutations in LRRK2 are the most common genetic cause of Parkinson’s disease. Despite substantial research efforts, the physiological and pathological role of this multidomain protein remains poorly defined. In this study, we used a systematic approach to construct the general protein-protein interactome around LRRK2, which was then evaluated taking into consideration the differential expression patterns and the co-expression behaviours of the LRRK2 interactors in 15 different healthy tissue types. The LRRK2 interactors exhibited distinct expression features in the brain as compared to the peripheral tissues analysed. Moreover, a high degree of similarity was found for the LRRK2 interactors in putamen, caudate and nucleus accumbens, thus defining a potential LRRK2 functional cluster within the striatum. The general LRRK2 interactome paired with the expression profiles of its members constitutes a powerful tool to generate tissue-specific LRRK2 interactomes. We exemplified the generation of the tissue-specific LRRK2 interactomes and explored the functions highlighted by the “core LRRK2 interactors” in the striatum in comparison with the cerebellum. Finally, we illustrated how the LRRK2 general interactome reported in this manuscript paired with the expression profiles can be used to trace the relationship between LRRK2 and specific interactors of interest, here focusing on the LRRK2 interactors belonging to the Rab protein family.

[1]  E. Tolosa,et al.  LRRK2 in Parkinson disease: challenges of clinical trials , 2020, Nature Reviews Neurology.

[2]  Eun-Jin Bae,et al.  The LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[3]  D. Berwick,et al.  LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same , 2019, Molecular Neurodegeneration.

[4]  A. Lees,et al.  Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. , 2019, Brain : a journal of neurology.

[5]  Liam J. McGuffin,et al.  PINOT: an intuitive resource for integrating protein-protein interactions , 2019, Cell Communication and Signaling.

[6]  S. Pizzi,et al.  Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions , 2019, Cell Death Discovery.

[7]  K. Patrick,et al.  LRRK2 regulates innate immune responses and neuroinflammation during Mycobacterium tuberculosis infection , 2019, bioRxiv.

[8]  J. Vilo,et al.  g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) , 2019, Nucleic Acids Res..

[9]  W. Seol,et al.  Rab GTPases as Physiological Substrates of LRRK2 Kinase , 2019, Experimental neurobiology.

[10]  G. Fink,et al.  Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control , 2019, Brain : a journal of neurology.

[11]  L. Civiero,et al.  The role of LRRK2 in cytoskeletal dynamics. , 2018, Biochemical Society transactions.

[12]  T. Iwatsubo,et al.  LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis , 2018, Proceedings of the National Academy of Sciences.

[13]  Ajay S. Kurani,et al.  Altered resting‐state functional connectivity of the putamen and internal globus pallidus is related to speech impairment in Parkinson's disease , 2018, Brain and behavior.

[14]  Tao Wu,et al.  Consistent decreased activity in the putamen in Parkinson's disease: a meta-analysis and an independent validation of resting-state fMRI , 2018, GigaScience.

[15]  T. Dawson,et al.  Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration , 2018, Molecular Neurodegeneration.

[16]  Judy H. Cho,et al.  Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease , 2018, Science Translational Medicine.

[17]  T. Iwatsubo,et al.  Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology. , 2018, Biochemical and biophysical research communications.

[18]  S. Pfeffer,et al.  Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase , 2017, The EMBO journal.

[19]  Yanhui Hu,et al.  Molecular Interaction Search Tool (MIST): an integrated resource for mining gene and protein interaction data , 2017, Nucleic Acids Res..

[20]  T. Gasser,et al.  Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils , 2017, The Biochemical journal.

[21]  S. Factor,et al.  LRRK2 levels in immune cells are increased in Parkinson’s disease , 2017, npj Parkinson's Disease.

[22]  Martin H. Schaefer,et al.  HIPPIE v2.0: enhancing meaningfulness and reliability of protein–protein interaction networks , 2016, Nucleic Acids Res..

[23]  M. Cookson,et al.  mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1 , 2016, Scientific Reports.

[24]  M. Ueffing,et al.  Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts , 2016, Proceedings of the National Academy of Sciences.

[25]  L. Abel,et al.  A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy , 2016, PLoS neglected tropical diseases.

[26]  Henning Hermjakob,et al.  A visual review of the interactome of LRRK2: Using deep-curated molecular interaction data to represent biology , 2015, Proteomics.

[27]  Claudia Manzoni,et al.  Computational analysis of the LRRK2 interactome , 2015, PeerJ.

[28]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[29]  D. Standaert,et al.  Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents , 2014, The Journal of comparative neurology.

[30]  P. Giunti,et al.  Inhibition of LRRK2 kinase activity stimulates macroautophagy , 2013, Biochimica et biophysica acta.

[31]  M. Rietschel,et al.  Comparison of gene expression profiles in the blood, hippocampus and prefrontal cortex of rats , 2013, In Silico Pharmacology.

[32]  R. DePaolo,et al.  Genetic variants associated with Crohn’s disease , 2013, The application of clinical genetics.

[33]  K. Marder,et al.  RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk , 2013, Neuron.

[34]  C. Manzoni,et al.  LRRK2 and Human Disease: A Complicated Question or a Question of Complexes? , 2012, Science Signaling.

[35]  Yusuke Nakamura,et al.  Meta‐analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis , 2011, Inflammatory bowel diseases.

[36]  J. Sanders,et al.  Leucine-Rich Repeat Kinase 2 (LRRK2) Cellular Biology: A Review of Recent Advances in Identifying Physiological Substrates and Cellular Functions , 2011, Journal of neurogenetics.

[37]  C. Wiessner,et al.  Regulation of LRRK2 Expression Points to a Functional Role in Human Monocyte Maturation , 2011, PloS one.

[38]  M. Kubo,et al.  LRRK2 is expressed in B-2 but not in B-1 B cells, and downregulated by cellular activation , 2010, Journal of Neuroimmunology.

[39]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[40]  M. S. Luciano,et al.  LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[41]  M. Nalls,et al.  Genetic variability at the PARK16 locus , 2010, European Journal of Human Genetics.

[42]  Guoping Fan,et al.  Signed weighted gene co-expression network analysis of transcriptional regulation in murine embryonic stem cells , 2009, BMC Genomics.

[43]  Thomas Schlitt,et al.  Protein-protein interaction databases: keeping up with growing interactomes , 2009, Human Genomics.

[44]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[45]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[46]  A. Singleton,et al.  Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls , 2008, Human mutation.

[47]  V. Baekelandt,et al.  Distribution of PINK1 and LRRK2 in rat and mouse brain , 2006, Journal of neurochemistry.

[48]  Alessandro Vespignani,et al.  Global protein function prediction from protein-protein interaction networks , 2003, Nature Biotechnology.

[49]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[50]  Richard S. J. Frackowiak,et al.  Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study , 1992, Annals of neurology.

[51]  A. Mirelman,et al.  Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. , 2015, JAMA neurology.

[52]  G. Halliday,et al.  Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. , 2013, Journal of Parkinson's disease.

[53]  S. Factor,et al.  LRRK2 levels in immune cells are increased in Parkinson’s disease , 2017, npj Parkinson's Disease.